the aetiology of chronic hypertension is not well understood. we have developed a new oral coronavirus drug candidate, b-729, as well as a new oral pd-l1 inhibitor. we are on track to initiate phase 1 clinical trials with our early-stage compounds, namely, b-101 as our oral pd-l1 inhibitor and b-161 as our oral RNA stabilizer. we are on track to initiate phase 3 clinical trials with our early-stage compounds.